Derivatives of (3S)-N-(biphenyl-2-ylmethyl)pyrrolidin-3-amine as selective noradrenaline reuptake inhibitors: Reducing P-gp mediated efflux by modulation of H-bond acceptor capacity

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 15, 2008, Pages 4355-4359

  Fish, Paul V ^a   Barta, Nancy S ^b   Gray, David L F ^b   Ryckmans, Thomas ^a   Stobie, Alan ^a   Wakenhut, Florian ^a   Whitlock, Gavin A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

^b PFIZER INC   (United States)

Author keywords

Carbamate; CNS penetration; H bond acceptor capacity; Noradrenaline reuptake inhibitor; NRI

Indexed keywords

AMIDE; ATOMOXETINE; CARBAMIC ACID DERIVATIVE; DOPAMINE; GLYCOPROTEIN P; N (BIPHENYL 2 YLMETHYL)PYRROLIDIN 3 AMINE DERIVATIVE; NORADRENALIN UPTAKE INHIBITOR; PF 3609113; REBOXETINE; SEROTONIN; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL STRAIN; CONTROLLED STUDY; DRUG PENETRATION; ENZYME INHIBITION; HUMAN; HYDROGEN BOND; MICRODIALYSIS; NONHUMAN; RAT;

ANIMALS; CENTRAL NERVOUS SYSTEM; COMBINATORIAL CHEMISTRY TECHNIQUES; HUMANS; MICROSOMES, LIVER; MOLECULAR STRUCTURE; PYRROLIDINES; RATS; SEROTONIN UPTAKE INHIBITORS; STEREOISOMERISM;

RATTUS;

EID: 47749116831     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.06.071     Document Type: Article

References (29)

1. Babu R.P.K., and Maiti S.N. Heterocycles 69 (2006) 539
2. For a recent review of new chemical entities, see:. Walter M.W. Drug Dev. Res. 65 (2005) 97
3. Ledbetter M. Neuropsychol. Dis. Treat. 2 (2006) 455
4. Hajos M., Fleishaker J.C., Filipiak-Reisner J.K., Brown M.T., and Wong E.H.F. CNS Drug Rev. 10 (2004) 23
5. Middleton D.S., Andrews M., Glossop P., Gymer G., Jessiman A., Johnson P.S., MacKenny M., Pitcher M.J., Rooker A., Stobie A., Tang K., and Morgan P. Bioorg. Med. Chem. Lett. 16 (2006) 1434
6. Fray M.J., Bish G., Brown A.D., Fish P.V., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 16 (2006) 4345
7. Fray M.J., Bish G., Fish P.V., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 16 (2006) 4349
8. Fish P.V., Fray M.J., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 17 (2007) 2022
9. Whitlock G.A., Blagg J., and Fish P.V. Bioorg. Med. Chem. Lett. 18 (2008) 596
10. Fish P.V., Deur C., Gan X., Greene K., Hoople D., Mackenny M., Para K.S., Reeves K., Ryckmans T., Stiff C., Stobie A., Wakenhut F., and Whitlock G.A. Bioorg. Med. Chem. Lett. 18 (2008) 2562
11. Whitlock G.A., Fish P.V., Fray M.J., Stobie A., and Wakenhut F. Bioorg. Med. Chem. Lett. 18 (2008) 2896
12. Fish P.V., Ryckmans T., Stobie A., and Wakenhut F. Bioorg. Med. Chem. Lett. 18 (2008) 1795
13. Middleton, D. S. Abstracts of Papers, 230th ACS National Meeting, Washington, DC, United States, Aug 28-Sep 1, 2005, MEDI-288.
14. Whitlock, G. A.; Wakenhut, F.; Stobie, A.; Fish, P. V.; Fray, M. J. Abstracts of Papers, 233rd ACS National Meeting, Chicago, IL, United States, March 25-29, 2007, MEDI-019.
15. Andrews, M. A; Brown, A. B.; Fish, P. V.; Fray, M. J.; Lansdell, M.; Ryckmans, T.; Stobie, A.; Wakenhut, F.; Whitlock, G. A.; Gray D. L. WO Patent 064351, 2006.
16. Wakenhut F., Fish P.V., Fray M.J., Stobie A., and Whitlock G.A. Bioorg. Med. Chem. Lett. 18 (2008) 4308
17. 2+) (L-type diltiazem site).
18. Preferred examples in Table 2 had calculated properties for ligand efficiency (LE ≥ 0.45) and ligand-lipophilic efficiency (LLE ≥ 5.0) consistent with drug-like chemical space. For an analysis of drug-like concepts, especially lipophilicity, see:. Leeson P.D., and Springthorpe B. Nat. Rev. Drug Dis. 6 (2007) 881
19. Mahar Doan K.M., Humphreys J.E., Webster L.O., Wring S.A., Shampine L.J., Serabjit-Singh C.J., Adkison K.K., and Polli J.W. J. Pharmacol. Exp. Ther. 303 (2002) 1029
20. Hitchcock S.A., and Pennington L.D. J. Med. Chem. 49 (2006) 1
21. The CNS analysis was limited by an incomplete set of in vivo data and so the correlation was performed against performance in the in vitro MDCK-mdr1 cell line.
22. For a substrate model of the P-gp transporter, see:. Seelig A. Eur. J. Biochem. 251 (1998) 252
23. Abraham M.H., Duce P.P., Prior D.V., Barratt D.G., Morris J.J., and Taylor P.J. J. Chem. Soc., Perkin Trans. 2 (1989) 1355
24. Abraham M.H., Grellier P.L., Prior D.V., Morris J.J., and Taylor P.J. J. Chem. Soc., Perkin Trans. 2 (1990) 521
25. 2 (1.47). See:. Laurence C., and Berthelot M. Persp. Drug Disc. Des. 18 (2000) 39 and references therein
26. Graton J., Berthelot M., and Laurence C. J. Chem. Soc., Perkin Trans. 2 (2001) 2130
27. Deecher D.C., Beyer C.E., Johnston G., Bray J., Shah S., Abou-Gharbia M., and Andree T.H. J. Pharmacol. Exp. Ther. 318 (2006) 657
28. i = 2.5 nM (n = 2).
29. +). For 11b D-tartrate salt: mp 117 °C.